Risk factors
Scholar Rock Holding (SRRK) risk factors
Item 1A of every Scholar Rock Holding Corp. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
69 risks, 14 new, 12 dropped, 24 reworded since the prior year. Transitioning from clinical development to commercialization for apitegromab in the United States and Europe.
Filed Mar 03, 2026 - FY2024 10-K risk factors
67 risks. Company is a clinical-stage biopharmaceutical firm reliant on pipeline candidates apitegromab and SRK-181.
Filed Feb 27, 2025